Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Texas attorney general opens investigation into Walmart's opioid sales

Published 06/28/2022, 06:43 PM
Updated 06/28/2022, 10:17 PM
© Reuters. FILE PHOTO: Walmart's logo is seen outside one of the stores in Chicago, Illinois, U.S., November 20, 2018. REUTERS/Kamil Krzaczynski

By Dietrich Knauth

(Reuters) -Texas Attorney General Ken Paxton said on Tuesday he was investigating whether Walmart (NYSE:WMT) improperly filled prescriptions and failed to report suspicious orders when selling opioid drugs.

Paxton said he had opened a civil investigation into Walmart's potential violations of the Texas Deceptive Trade Practices Act relating to the promotion, sale, dispensing and distribution of prescription opioids.

The investigation focuses on Walmart's compliance with a requirement to submit documentation related to its opioid orders to the U.S. Drug Enforcement Administration and all state agencies in Texas, Paxton said.

"I have fought for Texans who have been tragically impacted by the illegal marketing and sale of opioids, which have caused addiction and the untimely deaths of thousands of people each year," Paxton said. "I am committed to holding pharmacies accountable if they played a role in this devastating epidemic."

Walmart said it would answer the Texas Attorney General’s questions and that it was confident in its record on opioid safety.

The company's pharmacists have refused to fill hundreds of thousands of potentially problematic opioid prescriptions, and it has been chastised for being too cautious at times - including by the Texas Medical Board, Walmart spokesman Randy Hargrove said.

"Walmart and our pharmacists are torn between the demands on pharmacists imposed by opioids plaintiffs on one side and health agencies and regulators on the other, and patients are caught in the middle," Hargrove said.

The federal government separately sued Walmart over its alleged failure to report suspicious opioid orders in 2020, and many of the examples used in its complaint involved Texas prescriptions.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

That lawsuit was put on hold late last year while the U.S. Supreme Court considered a separate case involving the criminal conviction of two doctors found guilty of misusing their medical licenses to fill thousands of prescriptions for addictive pain medications.

The Supreme Court decided that case on Monday, ruling unanimously in favor of the two doctors, who argued that their trials were unfair because jurors were not instructed to consider whether they had "good faith" reasons to believe their numerous opioid prescriptions were medically valid.

The federal government's lawsuit against Walmart is scheduled to resume on July 11.

Walmart, along with two pharmacy chain operators, was found liable in November for fueling the opioid epidemic in two Ohio counties. The judge in that case held a second trial to determine the amount that Walmart and its co-defendants must pay to abate the opioid crisis in the two counties, but has not yet made a ruling.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.